Puma Biotechnology reports developments for a biopharmaceutical company built around oncology drug commercialization and development. Company news commonly centers on NERLYNX®, its oral neratinib product for HER2-positive breast cancer, including net product revenue, cost of sales, royalty revenue and financial outlook tied to demand for the therapy.
Updates also cover alisertib, a selective, orally administered aurora kinase A inhibitor licensed for development and commercialization. Puma describes the ALISCA™-Lung1 Phase II trial in extensive-stage small cell lung cancer and the ALISCA™-Breast1 Phase II trial in HER2-negative, HR-positive metastatic breast cancer, along with employee inducement equity awards under Nasdaq Listing Rule 5635(c)(4) and investor conference activity.
Puma Biotechnology (NASDAQ: PBYI) reported Q1 2026 results and raised 2026 guidance after increased demand for NERLYNX. Q1 product revenue was $42.0M; GAAP net loss was $3.8M (‑$0.07/share). Puma raised full‑year 2026 revenue to $222–$229M and net income to $16–$19M. Cash and marketable securities were $101.5M at March 31, 2026; debt was reduced to zero after a May 4, 2026 final payment.
Management cited interim ALISCA™ trial data and outlined H2 2026 enrollment expansions and a Q4 2026 data presentation.
Puma Biotechnology (NASDAQ: PBYI) announced on May 5, 2026 that its Compensation Committee approved inducement restricted stock unit awards covering 59,750 shares to six new non-executive employees under the 2017 Employment Inducement Incentive Award Plan.
The RSUs vest over three years: one-third on the first anniversary of the vesting commencement date (May 1, 2026) and one-sixth every six months thereafter, subject to continued service, and were granted pursuant to Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 7, 2026 to discuss first quarter 2026 financial results. Access via domestic dial-in 1-877-709-8150 or international 1-201-689-8354.
A live webcast and presentation slides will be available on the Investors section of the Puma Biotechnology website, with a replay archived for 90 days approximately one hour after the call.
Puma Biotechnology (NASDAQ: PBYI) disclosed inducement restricted stock unit awards totaling 31,625 shares granted April 1, 2026 to five new non‑executive employees under its 2017 Employment Inducement Incentive Award Plan.
The awards vest over a three‑year schedule, with one‑third vesting on the first anniversary of the vesting commencement date and one‑sixth vesting on each subsequent six‑month anniversary, subject to continued service, and were granted pursuant to Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) reported fourth quarter and full year 2025 results. Full-year product revenue was $204.1M and total revenue was $228.4M. GAAP net income for 2025 was $31.1M ($0.61 diluted). Cash, equivalents, and marketable securities totaled $97.5M; total debt fell to $22.5M. Puma provided 2026 guidance: total revenue $214–$221M and net income $10–$13M. Management highlighted continued profitability and upcoming alisertib clinical data presentations in 2026.
Puma Biotechnology (NASDAQ: PBYI) announced that Alan H. Auerbach, chairman and CEO, will present an overview at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 2:30 p.m. ET. The conference runs March 2–4 in Boston, and a live webcast and slides will be available on Puma's investor website and archived for 30 days.
Puma Biotechnology (NASDAQ: PBYI) will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, February 26, 2026 to discuss fourth quarter and full year 2025 financial results.
Dial-in numbers, a live webcast, presentation slides, and a replay archived for 90 days will be available via the company's Investors website.
Puma Biotechnology (NASDAQ: PBYI) announced on February 3, 2026 that its Compensation Committee approved inducement restricted stock unit awards covering 14,750 shares for two new non-executive employees.
The awards, granted under Puma’s 2017 Employment Inducement Incentive Award Plan, vest over three years beginning February 1, 2026, and comply with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) licensed NERLYNX® (neratinib) is now available in Thailand via Specialised Therapeutics following Thai FDA approval in December 2024.
NERLYNX is approved as a single agent for extended adjuvant treatment of early-stage HR+ HER2+ breast cancer within 12 months of completing trastuzumab, and with capecitabine for advanced/metastatic HER2+ disease after two or more prior anti-HER2 regimens.
Clinical data cited include a reduction in five-year recurrence risk by up to 42% in early-stage HR+ patients and, in advanced disease, a 2.2-month mean PFS improvement and longer response duration (8.5 vs 5.6 months) with NERLYNX+capecitabine versus lapatinib+capecitabine.
Puma Biotechnology (NASDAQ: PBYI) announced that on January 6, 2026 its Compensation Committee approved inducement restricted stock unit awards covering 10,500 shares of common stock for three new non-executive employees.
The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan and vest over a three-year schedule: one-third vest on the first anniversary of the vesting commencement date (January 1, 2026), then one-sixth on each six-month anniversary thereafter, subject to continued service. The grants were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).